Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612742 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
A Phase 3 study, sponsored by BioSante Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,656
- Enrollment target
NCT00612742: Completed Phase 3 study, sponsored by BioSante Pharmaceuticals.
NCT00612742 is a Phase 3 study that has completed, run by BioSante Pharmaceuticals. The registered enrollment target is 3,656 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (374% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00612742, a Phase 3 study, has completed, sponsored by BioSante Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,656 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD in postmenopausal women with at least two points of cardiovascular risk and clinical diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
Interventions
- DRUG testosterone gel
- DRUG placebo gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,656 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
What the finished NCT00612742 record still lists
NCT00612742 is an interventional study that assigns participants to a tested intervention. Its 3,656 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (374% higher).
The record links to 0 conditions, and to 2 interventions - of which testosterone gel is the first listed.
NCT00612742 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00612742 about?
NCT00612742 is a clinical study titled "Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women". This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD in postmenopausal women with at least two points of cardiovascular risk and clinical diagnosis of Hypoactive Sexual ...
What is the current status of trial NCT00612742?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,656 participants. The study started on 2008-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00612742?
The interventions under investigation include: testosterone gel (DRUG), placebo gel (DRUG).
Who is sponsoring clinical trial NCT00612742?
This trial is sponsored by BioSante Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00612742's enrollment target sits among peer trials
3,656 67th of 2000 higher than 1,934 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
- NCT07249398 · 3,650 participants · NA
Influence of Social Media Ads on Food Choice - Master Protocol
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- NCT06354920 · 3,624 participants · NA
M-Well Bonding Bundle to Improve Patient-Physician Relationships
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia